drugset / Trial / NCT00075634

Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

NCT00075634

Phase 1 Completed 21 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of decitabine when given together with doxorubicin and cyclophosphamide in treating children with relapsed or refractory solid tumors or neuroblastoma. Drugs used in chemotherapy, such as decitabine, doxorubicin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Timeline

Start
2003-12
Primary completion
2007-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule Intravenous
Background Cyclophosphamide Other / unclassified Intravenous
Background Doxorubicin Other / unclassified Intravenous
Background Pegfilgrastim Protein / enzyme biologic Subcutaneous
Background filgrastim Protein / enzyme biologic Subcutaneous